Key clinical point: The COPD Assessment Test (CAT) is a valid tool to assess bronchiectasis.
Major finding: The CAT is positively correlated to the St. George’s Respiratory Questionnaire (r = 0.90, P < .0001) and inversely correlated to the Quality of Life-Bronchiectasis Respiratory Symptoms Scale (r = -0.75, P < .0001) and Leicester Cough Questionnaire score (r = -0.77, P < .0001).
Study details: Two cohorts of patients with bronchiectasis patients (n = 48, mean age = 67, and n = 83, mean age = 71) answered several questionnaires, including CAT.
Disclosures: The study was funded by Tenovus Scotland and the Chief Scientist Office through a research fellowship to an author. Another author reports support from GlaxoSmithKline /British Lung Foundation Chair of Respiratory Research and other relationships, including research grants and consulting fees, with GlaxoSmithKline and multiple other drugmakers. Other authors report no disclosures.
Finch S et al. CHEST. 2019 Nov 12.